What is the clinical evidence from this study?

Study design: Review. Population: Acute coronary syndromes and stable ischemic heart disease. Intervention: Short-duration dual antiplatelet therapy (1 to 3 months) vs. Prolonged dual antiplatelet therapy (≥12 months).

What does this research mean for the field?

Modern new-generation drug-eluting stents allow for the safe shortening of dual antiplatelet therapy to 1-3 months in high bleeding risk patients without compromising ischemic protection. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

What question did this study set out to answer?

The aim is to summarize the evolution of dual antiplatelet therapy (DAPT) regimens with new-generation drug-eluting stents (DES) and propose personalized approaches.

July 8, 2026Open Access

Evolution of Dual Antiplatelet Therapy in the Era of New-Generation Drug-Eluting Stents: Balancing Ischemic and Bleeding Risks

View Full Paper

Ask AI

Bookmark

Why the study?

Does short-duration DAPT followed by P2Y12 inhibitor monotherapy balance ischemic and bleeding risks in patients undergoing PCI with new-generation DES compared to prolonged DAPT?

Population

Patients undergoing percutaneous coronary intervention with new-generation drug-eluting stents for acute…

Comparison

Short-duration dual antiplatelet therapy… vs Prolonged DAPT (≥12 months).

Design

Review

Key result

Shortening dual antiplatelet therapy to 1 to 3 months followed by P2Y12 inhibitor monotherapy is a validated strategy for patients with new-generation drug-eluting stents at high bleeding risk.

Authors

AMAdilmyrza Mukhamedkali AZAssel Zholdysbayeva

Discussion

Member takes

Overview

Shorter DAPT post-DES reduces bleeding without excess thrombosis; confirms consensus on individualized regimens after PCI.

Key Points

The aim is to summarize the evolution of dual antiplatelet therapy (DAPT) regimens with new-generation drug-eluting stents (DES) and propose personalized approaches.
Narrative review of literature from PubMed, Scopus, and Web of Science (2015–2026)
Prioritized guideline documents from ESC and ACC/AHA and large randomized controlled trials such as TWILIGHT and MASTER DAPT
Utilized ischemic and bleeding risk scoring systems for therapy personalization.
First-generation DES required prolonged DAPT (≥12 months) due to delayed endothelialization and late stent thrombosis.
New-generation DES improved vascular healing, allowing for short-DAPT strategies (1 to 3 months) followed by P2Y12 inhibitor monotherapy in high bleeding risk patients.
Risk scoring systems like PRECISE-DAPT and ARC-HBR criteria are essential for determining appropriate therapy duration.

Structured PICO

Does short-duration DAPT followed by P2Y12 inhibitor monotherapy balance ischemic and bleeding risks in patients undergoing PCI with new-generation DES compared to prolonged DAPT?

Population

Patients undergoing percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) for acute coronary syndromes (ACS) or stable ischemic heart disease, particularly those at high bleeding risk (HBR).

Intervention

Short-duration dual antiplatelet therapy (DAPT) (1 to 3 months) followed by P2Y12 inhibitor monotherapy.

Comparator

Prolonged DAPT (≥12 months).

Outcome

Ischemic protection (prevention of stent thrombosis) and bleeding risk (major bleeding).

The paradigm of DAPT duration has shifted to personalized medicine, where short DAPT strategies are safe and effective for patients with new-generation DES, especially those at high bleeding risk.

Cite This Study

Mukhamedkali et al. (2026) conducted a review in Acute coronary syndromes and stable ischemic heart disease. Short-duration dual antiplatelet therapy (1 to 3 months) vs. Prolonged dual antiplatelet therapy (≥12 months) was evaluated. Shortening dual antiplatelet therapy to 1 to 3 months followed by P2Y12 inhibitor monotherapy is a validated strategy for patients with new-generation drug-eluting stents at high bleeding risk.

synapsesocial.com/papers/6a4de835d2ea289ef628300f https://doi.org/10.5281/zenodo.21223014

View Full Paper

Ask AI

Bookmark

July 8, 2026Open Access

Evolution of Dual Antiplatelet Therapy in the Era of New-Generation Drug-Eluting Stents: Balancing Ischemic and Bleeding Risks

View Full Paper

Ask AI

Bookmark

Why the study?

Does short-duration DAPT followed by P2Y12 inhibitor monotherapy balance ischemic and bleeding risks in patients undergoing PCI with new-generation DES compared to prolonged DAPT?

Population

Patients undergoing percutaneous coronary intervention with new-generation drug-eluting stents for acute…

Comparison

Short-duration dual antiplatelet therapy… vs Prolonged DAPT (≥12 months).

Design

Review

Key result

Shortening dual antiplatelet therapy to 1 to 3 months followed by P2Y12 inhibitor monotherapy is a validated strategy for patients with new-generation drug-eluting stents at high bleeding risk.

Authors

AMAdilmyrza Mukhamedkali AZAssel Zholdysbayeva

Discussion

Member takes

Overview

Shorter DAPT post-DES reduces bleeding without excess thrombosis; confirms consensus on individualized regimens after PCI.

Key Points

The aim is to summarize the evolution of dual antiplatelet therapy (DAPT) regimens with new-generation drug-eluting stents (DES) and propose personalized approaches.
Narrative review of literature from PubMed, Scopus, and Web of Science (2015–2026)
Prioritized guideline documents from ESC and ACC/AHA and large randomized controlled trials such as TWILIGHT and MASTER DAPT
Utilized ischemic and bleeding risk scoring systems for therapy personalization.
First-generation DES required prolonged DAPT (≥12 months) due to delayed endothelialization and late stent thrombosis.
New-generation DES improved vascular healing, allowing for short-DAPT strategies (1 to 3 months) followed by P2Y12 inhibitor monotherapy in high bleeding risk patients.
Risk scoring systems like PRECISE-DAPT and ARC-HBR criteria are essential for determining appropriate therapy duration.

Structured PICO

Does short-duration DAPT followed by P2Y12 inhibitor monotherapy balance ischemic and bleeding risks in patients undergoing PCI with new-generation DES compared to prolonged DAPT?

Population

Intervention

Short-duration dual antiplatelet therapy (DAPT) (1 to 3 months) followed by P2Y12 inhibitor monotherapy.

Comparator

Prolonged DAPT (≥12 months).

Outcome

Ischemic protection (prevention of stent thrombosis) and bleeding risk (major bleeding).

The paradigm of DAPT duration has shifted to personalized medicine, where short DAPT strategies are safe and effective for patients with new-generation DES, especially those at high bleeding risk.

Cite This Study

synapsesocial.com/papers/6a4de835d2ea289ef628300f https://doi.org/10.5281/zenodo.21223014

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark